HomeInsightsStock Comparison

Novartis India Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Novartis India Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 21, 2025

Key Highlights

  • The Latest Trading Price of Novartis India Ltd is ₹ 1014 as of 20 Jun 15:30.
  • The P/E Ratio of Novartis India Ltd is 0 as of March 2023 .The P/E Ratio of Sandu Pharmaceuticals Ltd is 33.3 as of March 2023.
  • The Market Cap of Novartis India Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sandu Pharmaceuticals Ltd is ₹ 50.43 crore as of March 2023.
  • The revenue of Novartis India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 14.14 crore as compare to the Dec '24 revenue of ₹ 18.4 crore. This represent the decline of -23.15%.
  • The ebitda of Novartis India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 0.52 crore as compare to the Dec '24 ebitda of ₹ 1.02 crore. This represent the decline of -49.02%.
  • The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.11 crore to ₹ 0.33 crore over 8 quarters. This represents a CAGR of 73.21% .
  • The Dividend Payout of Novartis India Ltd changed from 244.84 % on March 2020 to 72.43 % on March 2024 . This represents a CAGR of -21.62% over 5 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 52.93 % on March 2024 . This represents a CAGR of 9.86% over 4 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Novartis India Ltd

  • Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
  • The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
  • The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
  • In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
  • In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Sandu Pharmaceuticals Ltd

  • Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
  • The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
  • This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
  • Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
  • Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

Novartis India Ltd News Hub

News

Novartis India schedules AGM

Novartis India announced that the 77th Annual General Meeting(AGM) of the company will be ...

Read more

10 May 2025 09:38

News

Board of Novartis India recommends final dividend

Novartis India announced that the Board of Directors of the Company at its meeting held on...

Read more

10 May 2025 09:38

News

Novartis India to announce Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 9 May 2025....

Read more

28 Mar 2025 09:32

News

Novartis India to hold board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 28 January ...

Read more

28 Dec 2024 09:37

News

Novartis India schedules board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 October ...

Read more

28 Sep 2024 10:07

News

Novartis India to declare Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 29 July 202...

Read more

28 Jun 2024 17:50

Sandu Pharmaceuticals Ltd News Hub

News

Board of Sandu Pharmaceuticals recommends final dividend

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

29 May 2025 10:50

News

Sandu Pharmaceuticals to table results

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

19 May 2025 10:56

News

Sandu Pharmaceuticals to convene board meeting

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 F...

Read more

05 Feb 2025 12:52

News

Sandu Pharmaceuticals declare Quarterly Result

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 N...

Read more

05 Nov 2024 13:43

News

Board of Sandu Pharmaceuticals recommends final dividend

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

13 Aug 2024 09:53

News

Sandu Pharmaceuticals AGM scheduled

Sandu Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company ...

Read more

13 Aug 2024 09:53

SWOT Analysis Of Novartis India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Sandu Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Novartis India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Novartis India Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Novartis India Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Novartis India Ltd is 2,505 Cr while Market cap of Sandu Pharmaceuticals Ltd is 48 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Novartis India Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Sandu Pharmaceuticals Ltd?

As of June 21, 2025, the Novartis India Ltd stock price is INR ₹1014.85. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹50.5.

How do dividend payouts of Novartis India Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions